Tg Therapeutics (TGTX) Total Current Liabilities (2010 - 2026)

Tg Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $187.1 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 16.79% year-over-year to $187.1 million; the TTM figure through Mar 2026 stood at $187.1 million (up 16.79% YoY), while the FY2025 annual figure was $153.8 million, up 69.57% from the prior year.
• Total Current Liabilities was $187.1 million for Q1 2026 at Tg Therapeutics, up from $153.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $187.1 million in Q1 2026 to a low of $36.4 million in Q3 2022.
• Historically, Total Current Liabilities has averaged $99.3 million across 5 years, with a median of $90.7 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities tumbled 58.42% in 2022, then surged 116.92% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $53.2 million in 2022, then climbed by 0.98% to $53.7 million in 2023, then surged by 68.8% to $90.7 million in 2024, then jumped by 69.57% to $153.8 million in 2025, then increased by 21.69% to $187.1 million in 2026.
• The last three Total Current Liabilities figures came in at $187.1 million (Q1 2026), $153.8 million (Q4 2025), and $156.8 million (Q3 2025), per Business Quant data.